Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Everolimus in advanced pancreatic neuroendocrine tumor
NCT00510068Phase 3Completed
- Sponsor
- Novartis
- Start
- Jul 2007
- Primary completion
- Feb 2010
- Modality
- Small Molecules
- Countries
- 18
01
Overview
A Phase 3 trial of everolimus in Pancreatic neuroendocrine tumor (PanNET), sponsored by Novartis. Started Jul 2007; status: completed.
02
Drugs
everolimus
03
Conditions
Pancreatic neuroendocrine tumor (PanNET)
Beyond the preview
Go deeper on NCT00510068.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00510068.